AXSM News and Press, Axsome Therapeutics Inc. From 05/03/24

2024-05-03 12:54:44 ET More on Axsome Therapeutics Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript Axsome Therapeutics stock rises on upgrade to Overweight at Morgan Sta...

2024-05-01 10:45:03 ET XPeng Inc (XPEV) XPEV is trading UP for the last 5 days, and it at trading at $8.16 with volume of 3,591,457 and a one day change of $0.03 (0.31%). XPeng Inc has a 52-week low of 6.55 and a 52-week high of $23.62. The business's 50-day moving average price is ...

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Ment...

2024-04-29 10:08:15 ET More on Axsome Therapeutics Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript Baird starts Axsome at outperform, cites upcoming data Axsome ...

2024-04-25 18:28:44 ET Summary Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some advantages over currently approved MDD therapies, su...

2024-04-24 11:59:30 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Neurocrine succeeds in mid-stage trial for Takeda-partnered depression d...

2024-04-16 13:17:12 ET Summary Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achieved with statistical significance. The Major Depres...

AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) --...

2024-04-10 10:40:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Markets appear to have...

2024-04-10 10:15:00 ET Exciting growth stocks are highly coveted, but some fly under the radar for various reasons. And this gives astute investors the opportunity to pounce before their shares rise significantly. Mid-cap biotechs Madrigal Pharmaceuticals (NASDAQ: MDGL) and Ax...